image
Healthcare - Medical - Devices - NASDAQ - US
$ 2.27
-5.42 %
$ 99.5 M
Market Cap
-2.1
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one RPID stock under the worst case scenario is HIDDEN Compared to the current market price of 2.27 USD, Rapid Micro Biosystems, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one RPID stock under the base case scenario is HIDDEN Compared to the current market price of 2.27 USD, Rapid Micro Biosystems, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one RPID stock under the best case scenario is HIDDEN Compared to the current market price of 2.27 USD, Rapid Micro Biosystems, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart RPID

image
$4.0$4.0$3.5$3.5$3.0$3.0$2.5$2.5$2.0$2.0$1.5$1.5$1.0$1.0$0.5$0.5Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
28.1 M REVENUE
24.57%
-49.9 M OPERATING INCOME
11.75%
-46.9 M NET INCOME
10.63%
-44.2 M OPERATING CASH FLOW
2.06%
36.7 M INVESTING CASH FLOW
-13.04%
203 K FINANCING CASH FLOW
36.24%
8.22 M REVENUE
8.07%
-10.2 M OPERATING INCOME
15.03%
-9.67 M NET INCOME
14.63%
-9.91 M OPERATING CASH FLOW
-15.22%
4.86 M INVESTING CASH FLOW
174.38%
-6 K FINANCING CASH FLOW
-9.84%
Balance Sheet Rapid Micro Biosystems, Inc.
image
Current Assets 80.9 M
Cash & Short-Term Investments 50.7 M
Receivables 7.52 M
Other Current Assets 22.7 M
Non-Current Assets 17.3 M
Long-Term Investments 0
PP&E 16.4 M
Other Non-Current Assets 896 K
51.68 %7.67 %23.08 %16.66 %Total Assets$98.2m
Current Liabilities 17.6 M
Accounts Payable 2.54 M
Short-Term Debt 1.21 M
Other Current Liabilities 13.8 M
Non-Current Liabilities 5.25 M
Long-Term Debt 4.95 M
Other Non-Current Liabilities 298 K
11.11 %5.32 %60.55 %21.71 %Total Liabilities$22.8m
EFFICIENCY
Earnings Waterfall Rapid Micro Biosystems, Inc.
image
Revenue 28.1 M
Cost Of Revenue 21 M
Gross Profit 7.01 M
Operating Expenses 56.9 M
Operating Income -49.9 M
Other Expenses -3.03 M
Net Income -46.9 M
30m30m20m20m10m10m00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)28m(21m)7m(57m)(50m)3m(47m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
24.99% GROSS MARGIN
24.99%
-177.96% OPERATING MARGIN
-177.96%
-167.16% NET MARGIN
-167.16%
-62.23% ROE
-62.23%
-47.76% ROA
-47.76%
-61.04% ROIC
-61.04%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Rapid Micro Biosystems, Inc.
image
00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)(60m)(60m)(70m)(70m)202020202021202120222022202320232024202420252025
Net Income -46.9 M
Depreciation & Amortization 3.36 M
Capital Expenditures -1.36 M
Stock-Based Compensation 3.87 M
Change in Working Capital -4.77 M
Others -2.74 M
Free Cash Flow -45.5 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Rapid Micro Biosystems, Inc.
image
RPID has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 18
6. Ownership
Insider Ownership Rapid Micro Biosystems, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
41.4 K USD 1
3-6 MONTHS
142 K USD 4
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Rapid Micro Biosystems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) LEXINGTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced the grants (i) on March 3, 2025, of 50,000 restricted stock units (“RSUs”) of the Company's Class A common stock (“Common Stock”) as a material inducement to employment of one new employee and (ii) on March 10, 2025, of non-qualified stock options to purchase an aggregate of 250,000 shares of Common Stock (the “Options”) and 174,000 RSUs as a material inducement to employment to two new employees. All such equity awards were made under the Company's Inducement Plan, as amended (the “Inducement Plan”) and were approved by a majority of the independent directors of the Board of Directors or a duly authorized committee thereof in accordance with Nasdaq Listing Rule 5635(c)(4). The equity awards are subject to the terms and conditions of the Inducement Plan, and the terms and conditions of the applicable stock option and RSU award agreements covering the grants. globenewswire.com - 1 month ago
Rapid Micro Biosystems, Inc. (RPID) Q4 2024 Earnings Call Transcript Rapid Micro Biosystems, Inc. (NASDAQ:RPID ) Q4 2024 Earnings Conference Call February 28, 2025 8:00 AM ET Company Participants Mike Beaulieu – Vice President, Investor Relations and Corporate Communications Rob Spignesi – President and Chief Executive Officer Sean Wirtjes – Chief Financial Officer Conference Call Participants Dan Arias – Stifel Paul Knight – KeyBanc Brendan Smith – TD Cowen Operator Thank you for standing by. My name is Eloisa, and I will be your conference operator today. seekingalpha.com - 2 months ago
Rapid Micro Biosystems, Inc. (RPID) Reports Q4 Loss, Tops Revenue Estimates Rapid Micro Biosystems, Inc. (RPID) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.26 per share a year ago. zacks.com - 2 months ago
Rapid Micro Biosystems Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Guidance LEXINGTON, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced its financial results for the fourth quarter and full year ended December 31, 2024. globenewswire.com - 2 months ago
Rapid Micro Biosystems Announces Global Distribution and Collaboration Agreement with the Life Science business of Merck KGaA, Darmstadt, Germany Significantly extends commercial reach of Growth Direct through expanded global sales channels; enables opportunities for collaboration on supply chain efficiencies, services, and joint product development. Significantly extends commercial reach of Growth Direct through expanded global sales channels; enables opportunities for collaboration on supply chain efficiencies, services, and joint product development. globenewswire.com - 2 months ago
Rapid Micro Biosystems to Participate in Upcoming Investor Conferences LEXINGTON, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that the Company will participate in the following investor conferences. globenewswire.com - 2 months ago
Rapid Micro Biosystems to Announce Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025 LEXINGTON, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release fourth quarter and full year 2024 financial results prior to the market open on Friday, February 28, 2025. globenewswire.com - 2 months ago
Rapid Micro Biosystems Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Revenue LEXINGTON, Mass., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced preliminary unaudited fourth quarter and full year 2024 revenue. globenewswire.com - 3 months ago
Rapid Micro Biosystems to Present at 43ʳᵈ Annual J.P. Morgan Healthcare Conference LEXINGTON, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference. globenewswire.com - 3 months ago
Rapid Micro Biosystems to Participate in the Stifel 2024 Healthcare Conference LEXINGTON, Mass., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that the Company will participate in the Stifel 2024 Healthcare Conference. globenewswire.com - 5 months ago
Rapid Micro Biosystems, Inc. (RPID) Q3 2024 Earnings Call Transcript Rapid Micro Biosystems, Inc. (NASDAQ:RPID ) Q3 2024 Results Conference Call November 1, 2024 9:00 AM ET Company Participants Michael Beaulieu - CFA, VP, IR & Corporate Communications Robert Spignesi - President & CEO Sean Wirtjes - CFO Conference Call Participants Brendan Smith - TD Cowen Dan Arias - Stifel Operator Thank you for standing by. My name is Novi, and I will be your conference operator today. seekingalpha.com - 6 months ago
Rapid Micro Biosystems, Inc. (RPID) Reports Q3 Loss, Tops Revenue Estimates Rapid Micro Biosystems, Inc. (RPID) came out with a quarterly loss of $0.26 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.31 per share a year ago. zacks.com - 6 months ago
8. Profile Summary

Rapid Micro Biosystems, Inc. RPID

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 99.5 M
Dividend Yield 0.00%
Description Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in North America, Europe, and Asia. The company offers Growth Direct platform, which includes Growth Direct system, proprietary consumables, lab information management system connection software, and comprehensive customer support and validation services. Its platform automates and modernizes the manual microbial quality control (MQC) testing workflows for therapeutic modalities, such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company also provides installation and verification, technical training, and support services. Its solutions are used in environmental monitoring, water testing, bioburden, and sterility release testing applications. The company was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. in January 2007. Rapid Micro Biosystems, Inc. was incorporated in 2006 and is headquartered in Lowell, Massachusetts.
Contact 1001 Pawtucket Boulevard West, Lowell, MA, 01854 https://www.rapidmicrobio.com
IPO Date July 15, 2021
Employees 163
Officers Mr. Robert G. Spignesi Jr. Chief Executive Officer, President & Director Mr. Sean M. Wirtjes CPA Chief Financial Officer Mr. James Xu Senior Vice President of Legal & Secretary Mr. Michael Beaulieu C.F.A. Vice President of Investor Relations & Corporate Communications Mr. John J. Addington Wilson Chief Operating Officer Ms. Julie Jarvie Senior Vice President of Human Resources